POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose is a carbohydrate that provides calories and may help prevent ketosis. Sodium chloride provides sodium and chloride ions, which are critical for extracellular fluid balance and osmotic pressure.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium and chloride are not metabolized. |
| Excretion | Renal excretion of potassium (90%) and chloride (95%); negligible biliary/fecal elimination. Dextrose and sodium chloride components are metabolized and excreted renally. |
| Half-life | Potassium: ~12 hours (terminal half-life) in patients with normal renal function; prolonged in renal impairment. Dextrose and sodium chloride: minutes to hours depending on metabolic state. |
| Protein binding | Potassium: <2% bound; chloride: minimal binding; dextrose and sodium not protein-bound. |
| Volume of Distribution | Potassium: 0.5-0.7 L/kg (total body water). Chloride: 0.2-0.3 L/kg (extracellular fluid). Dextrose: 0.2-0.3 L/kg (extracellular fluid initially, then intracellular metabolism). |
| Bioavailability | Intravenous: 100% bioavailable. Not administered orally for this formulation. |
| Onset of Action | Intravenous: rapid (within minutes) for electrolyte effects; dextrose utilization begins immediately. |
| Duration of Action | Intravenous: 1-2 hours for electrolyte correction; dextrose effects last until metabolized (typically minutes to hours). Clinical monitoring is required. |
| Molecular Weight | 74.55 |
Intravenous infusion; rate not to exceed 10 mEq/h potassium; typical adult dose: 20-40 mEq potassium per liter of IV fluid, administered at 100-200 mL/h, based on electrolyte needs.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce potassium to 50% of standard dose; GFR <30 mL/min: contraindicated unless monitored closely with serum potassium. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: monitor potassium and reduce dose if needed; Child-Pugh Class C: use with caution, typically reduce dose by 50% due to risk of hyperkalemia. |
| Pediatric use | Weight-based: 0.5-1 mEq/kg per day potassium, infused at a rate not exceeding 0.5 mEq/kg/h; max 3 mEq/kg/day; adjust fluid rate for dextrose and sodium based on age and clinical status. |
| Geriatric use | Elderly patients: start at lower end of dosing range (e.g., 20 mEq potassium per liter), infuse at slower rate (max 5 mEq/h), monitor renal function and serum potassium frequently due to decreased renal reserve. |
| 1st trimester | Potassium chloride, dextrose, and sodium chloride are generally considered safe in the first trimester when used as a source of electrolytes and hydration. No teratogenic effects have been reported at therapeutic doses. |
| 2nd trimester | Safe for use in the second trimester as an electrolyte replenisher and hydration solution. Monitor serum electrolytes and fluid balance. |
| 3rd trimester | Safe in the third trimester for maintenance of electrolyte balance and hydration. Use with caution in preeclampsia or renal impairment. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium, dextrose, and sodium cross the placenta freely via passive diffusion and active transport mechanisms. Fetal serum levels equilibrate with maternal levels. |
| Breastfeeding | Potassium, dextrose, and sodium are normal constituents of breast milk. No adverse effects on breastfed infants are expected from maternal intravenous administration at therapeutic doses. Compatible with breastfeeding. |
| Lactation Rating | L1 |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride are essential nutrients; no teratogenic effects are expected at therapeutic doses. However, electrolyte imbalances (hyperkalemia, hypernatremia, hyperglycemia) may pose fetal risks, especially in the third trimester. Dextrose may cause fetal hyperinsulinemia and rebound hypoglycemia if maternal hyperglycemia occurs. First trimester: no known teratogenicity. Second and third trimesters: risks are related to maternal electrolyte disturbances rather than direct teratogenicity. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, chloride, glucose) and fluid balance. Assess fetal heart rate and uterine activity if administered during labor. Monitor for signs of hyperkalemia (ECG changes), hypernatremia, or fluid overload. In dextrose-containing solutions, monitor maternal blood glucose, especially in diabetes or gestational diabetes. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Electrolyte imbalances may impact ovulation and implantation, but this is unlikely with appropriate use. |
■ FDA Black Box Warning
Potassium chloride concentrate for injection must be diluted before use. Administration of undiluted potassium chloride may cause cardiac arrest and death.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaHyperglycemia with dextrose contraindication (e.g., diabetic ketoacidosis without electrolytes)Hypersensitivity to any component
| Precautions | Hyperkalemia: Can cause cardiac arrest; monitor serum potassium levels and ECG during administration., Dilution required: Concentrated potassium chloride must be diluted to avoid fatal hyperkalemia., Renal impairment: Use with caution; may lead to potassium accumulation., Cardiac disease: Increased risk of arrhythmias; monitor closely., Extravasation: Can cause tissue necrosis if potassium leaks into surrounding tissue., Dextrose administration: May cause hyperglycemia; use with caution in diabetes. |
| Food/Dietary | Avoid excessive ingestion of potassium-rich foods (e.g., bananas, oranges, leafy greens) and salt substitutes containing potassium chloride. No other specific dietary restrictions. |
| Clinical Pearls | This solution is a hypotonic maintenance fluid with potassium supplementation. Use with caution in patients with renal impairment, hyperkalemia, or conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, potassium-sparing diuretics). Monitor serum potassium and glucose levels, especially in diabetic patients. Avoid in patients with severe hypovolemia or hyponatremia. Do not exceed infusion rate of 10 mEq/h potassium. Inspect for particulate matter and discoloration before use. |
| Patient Advice | Report any signs of hyperkalemia such as muscle weakness, palpitations, or paresthesias. · Inform your healthcare provider if you have kidney problems or are taking potassium supplements or salt substitutes. · This solution contains dextrose; if you have diabetes, your blood sugar may increase. · Do not adjust the infusion rate yourself; report any pain, redness, or swelling at the IV site. |
Loading safety data…